Section Arrow
Quote
CLDI.NYSE-M
- Calidi Biotherapeutics Inc
Quotes are at least 15-min delayed:2026/08/07 11:25 EDT
Regular Hours
Last
 1.7221
-0.0679 (-3.79%)
Day High 
1.79 
Prev. Close
1.79 
1-M High
2.4 
Volume 
59.73K 
Bid
1.73
Ask
1.76
Day Low
1.71 
Open
1.79 
1-M Low
1.4832 
Market Cap 
2.16M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.7 
20-SMA 1.83 
50-SMA 2.32 
52-W High 96.9504 
52-W Low 1.4832 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-66.72/-8.80
Enterprise Value
3.21M
Balance Sheet
Book Value Per Share
4.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.37
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CELZCreative Medical Technology Holdings1.4399+0.2899+25.21%-- 
IOVAIovance Biotherapeutics6.17-0.04-0.64%-- 
ARDXArdelyx4.225-0.645-13.24%-- 
ENSCEnsysce Biosciences0.49755-0.02675-5.10%-- 
REPLReplimune Group12.155-0.705-5.48%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed HighGrade Glioma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.